Exelixis (EXEL) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Exelixis (EXEL) over the past year, gaining 298.5% versus a gain of 55.2%. Over five years, RVMD leads with a +604.1% price change compared with +174.3% for EXEL. Revolution Medicines is the larger company by market cap ($40.67 billion vs $14.83 billion), about 2.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EXEL | RVMD |
|---|---|---|
| Share price | $59.86 | $189.76 |
| Market cap | $14.83B | $40.67B |
| 1-day change | +1.42% | +0.87% |
| YTD return | +36.57% | +138.24% |
| 1-year return | +55.20% | +298.53% |
| 5-year return | +174.34% | +604.12% |
| P/E ratio (TTM) | 18.59 | — |
| Forward P/E | 14.01 | — |
| EPS (TTM) | $3.22 | $-8.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.32B | $0 |
| Revenue growth (YoY) | +6.98% | — |
| Net income (latest FY) | $782.57M | $-1.13B |
| Gross margin | 96.39% | — |
| Operating margin | 37.59% | — |
| Net margin | 33.73% | — |
| 52-week high | $61.14 | $224.31 |
| 52-week low | $33.76 | $47.28 |
| Distance from 52-week high | -2.09% | -15.40% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | -8.90% | +36.40% |
| Average volume | 2.34M | 1.93M |
| Shares outstanding | 247.78M | 214.34M |
| Employees | 1,077 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Revolution Medicines is about 2.7 times larger than Exelixis by market value ($40.67B vs $14.83B).
- RVMD has outperformed EXEL by 243.3 percentage points over the past year.
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
EXEL vs RVMD FAQ
Which is bigger, Exelixis or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.67B compared with $14.83B for Exelixis (EXEL).
Which stock has performed better over the past year, EXEL or RVMD?
RVMD returned +298.53% over the past 12 months, compared with +55.20% for EXEL (price return, excluding dividends). Past performance does not predict future results.
Are Exelixis and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.